Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Investing Activities: 2020-2025

Historic Cash from Investing Activities for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to -$25.2 million.

  • Arcutis Biotherapeutics' Cash from Investing Activities fell 129.78% to -$25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.8 million, marking a year-over-year increase of 156.86%. This contributed to the annual value of $28.8 million for FY2024, which is 84.01% down from last year.
  • Arcutis Biotherapeutics' Cash from Investing Activities amounted to -$25.2 million in Q3 2025, which was down 244.91% from $17.4 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Cash from Investing Activities high stood at $107.8 million for Q1 2023, and its period low was -$197.3 million during Q3 2022.
  • Over the past 3 years, Arcutis Biotherapeutics' median Cash from Investing Activities value was $17.4 million (recorded in 2025), while the average stood at $19.4 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Cash from Investing Activities tumbled by 5,783.15% in 2022 and then surged by 604.39% in 2023.
  • Quarterly analysis of 5 years shows Arcutis Biotherapeutics' Cash from Investing Activities stood at $23.5 million in 2021, then surged by 79.59% to $42.2 million in 2022, then slumped by 247.36% to -$62.2 million in 2023, then soared by 156.08% to $34.9 million in 2024, then slumped by 129.78% to -$25.2 million in 2025.
  • Its last three reported values are -$25.2 million in Q3 2025, $17.4 million for Q2 2025, and $11.8 million during Q1 2025.